Drug intelligence / Profile preview

CAP-1

Development stage: Phase 1
Modality: Peptides, Small Molecules
Administration: Subcutaneous, Intramuscular

Overview

CAP-1 is a synthetic peptide derived from the carcinoembryonic antigen (CEA), also known as CEA peptide-1. It is used experimentally to make vaccines that may help stimulate the body's immune system to recognize and kill cancer cells expressing CEA. The primary mechanism involves acting as a tumor-associated antigen to elicit an anti-tumor immune response in cancer immunotherapy settings[1]. CAP-1 has also been studied for its ability to inhibit HIV-1 infectivity in vitro, though it does not interfere with viral entry or early replication steps[4]. It is classified as a small molecule and belongs chemically to the class of n-phenylureas[2].

Other names: carcinoembryonic antigen peptide-1CEA peptide-1

Targets

HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)

Beyond the preview

Go deeper on CAP-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAP-1.

Explore the full profile